

UBE2N / UBC13 Antibody (C-Terminus)

Rabbit Polyclonal Antibody Catalog # ALS11740

Specification

UBE2N / UBC13 Antibody (C-Terminus) - Product Information

Application IHC Primary Accession P61088

Reactivity Human, Mouse, Rat

Host Rabbit
Clonality Polyclonal
Calculated MW 17kDa KDa

UBE2N / UBC13 Antibody (C-Terminus) - Additional Information

Gene ID 7334

Other Names

Ubiquitin-conjugating enzyme E2 N, 6.3.2.19, Bendless-like ubiquitin-conjugating enzyme, Ubc13, UbcH13, Ubiquitin carrier protein N, Ubiquitin-protein ligase N, UBE2N, BLU

Target/Specificity

peptide corresponding to 15 amino acids near the C-terminus of human UBC13

Reconstitution & Storage

Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles. Store undiluted.

Precautions

UBE2N / UBC13 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.


UBE2N / UBC13 Antibody (C-Terminus) - Protein Information

Name UBE2N

Synonyms BLU

Function

The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly- ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'- linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1- UBE2N heterodimer acts in concert with TRIM5 to generate





'Lys-63'- linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. Together with RNF135 and UB2V1, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production (PubMed:28469175" target="_blank">28469175, PubMed:31006531, PubMed:31006531, UBE2V1- UBE2N together with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'- linked polyubiquitination of TRAF6, a component of IL17A-mediated signaling pathway.


Cellular Location Nucleus. Cytoplasm

UBE2N / UBC13 Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

UBE2N / UBC13 Antibody (C-Terminus) - Images



Anti-UBE2N antibody IHC of human kidney.





Anti-UBE2N antibody IHC of human skin.

UBE2N / UBC13 Antibody (C-Terminus) - Background

The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes (By similarity).

UBE2N / UBC13 Antibody (C-Terminus) - References

Yamaguchi T.,et al.J. Biochem. 120:494-497(1996). Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. Lubec G.,et al.Submitted (DEC-2008) to UniProtKB. Zou W.,et al.Biochem. Biophys. Res. Commun. 336:61-68(2005). Hofmann R.M.,et al.Cell 96:645-653(1999).